Nathan A Pennell

List of Publications by Year
in descending order

156	16,748	81900 39	17105 122
papers	citations	h-index	g-index

163	163	163	28410
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comprehensive molecular profiling of lung adenocarcinoma. Nature, 2014, 511, 543-550.	27.8	4,572
2	Pan-cancer analysis of whole genomes. Nature, 2020, 578, 82-93.	27.8	1,966
3	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	13.7	1,395
4	Reactive microgliosis. Progress in Neurobiology, 1999, 57, 563-581.	5.7	1,074
5	Gene expressionâ€“based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine, 2008, 14, 822-827.	30.7	1,015
6	Efficacy of Selpercatinib in RET Fusionâ€“Positive Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2020, 383, 813-824.	27.0	505
7	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discovery, 2018, 8, 1548-1565.	9.4	422
8	Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 4417-4424.	1.6	405
9	Incidence of Pneumonitis With Use of ProgrammedÂDeath 1 and Programmed Death-Ligand 1 InhibitorsÂinÂNon-Small CellÂLungÂCancer. Chest, 2017, 152, 271-281.	0.8	381
10	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2017, 35, 1341-1367.	1.6	318
11	NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 230-241.	4.9	284
12	Adagrasib in Nonâ€“Small-Cell Lung Cancer Harboring a KRAS^{G12C} Mutation. New England Journal of Medicine, 2022, 387, 120-131.	27.0	269
13	Biomarker Testing for Patients With Advanced Nonâ€“Small Cell Lung Cancer: Real-World Issues and Tough Choices. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 531-542.	3.8	210
14	A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer. Thyroid, 2008, 18, 317-323.	4.5	185
15	Time to initial cancer treatment in the United States and association with survival over time: An observational study. PLoS ONE, 2019, 14, e0213209.	2.5	179
16	Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). Journal of Thoracic Oncology, 2018, 13, 1393-1399.	1.1	169
17	Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis. Journal of Neuroimmunology, 1998, 86, 1-12.	2.3	160
18	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptorâ€“Mutant Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2019, 37, 97-104.	1.6	159

#	Article	IF	Citations
19	Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab. Journal of Thoracic Oncology, 2018, 13, 1771-1775.	1.1	157
20	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncology, 2021, 7, 1167.	7.1	149
21	A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nature Communications, 2016, 7, 11428.	12.8	136
22	Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Advances, 2020, 4, 5966-5975.	5.2	124
23	ALK Status Testing in Nonâ€“Small Cell Lung Carcinoma. Journal of Molecular Diagnostics, 2013, 15, 341-346.	2.8	115
24	Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1547-1552.	7.1	115
25	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discovery, 2020, 10, 1514-1527.	9.4	108
26	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2020, 38, 1081.	1.6	101
27	Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer. Seminars in Oncology, 2015, 42, S3-S10.	2.2	96
28	Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC. Oncologist, 2009, 14, 399-411.	3.7	86
29	Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Nonâ€“Small-Cell Lung Cancer Using a Decision Analytic Model. JCO Precision Oncology, 2019, 3, 1-9.	3.0	81
30	Prospective Clinical Study of Precision Oncology in Solid Tumors. Journal of the National Cancer Institute, 2016, 108, .	6.3	70
31	ALK Status Testing in Nonâ€“Small-Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material. Journal of Thoracic Oncology, 2014, 9, 464-468.	1.1	57
32	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis. JCO Precision Oncology, 2017, 1, 1-15.	3.0	57
33	Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. Journal of Clinical Oncology, 2021, 39, 1165-1184.	1.6	54
34	Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Nonâ€“Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Clinical Lung Cancer, 2018, 19, e335-e348.	2.6	53
35	Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer: ECOG-ACRIN 5508. Journal of Clinical Oncology, 2019, 37, 2360-2367.	1.6	52
36	XL647â€”A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib. Journal of Thoracic Oncology, 2012, 7, 219-226.	1.1	51

#	Article	IF	Citations
37	Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. PLoS ONE, 2018, 13, e0197743.	2.5	50
38	METExon 14 Skipping Mutations in Nonâ€“Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. JCO Precision Oncology, 2021, 5, 653-663.	3.0	50
39	EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC). Lung Cancer, 2014, 86, 158-163.	2.0	47
40	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. JAMA Network Open, 2022, 5, e224304.	5.9	43
41	RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib. Journal of Thoracic Oncology, 2014, 9, 1714-1719.	1.1	40
42	Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer, 2017, 112, 181-187.	2.0	40
43	Risk of thromboembolism in patients with ALKâ€•and EGFRâ€•mutant lung cancer: A cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 822-829.	3.8	37
44	Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. Investigational New Drugs, 2014, 32, 362-368.	2.6	36
45	A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. Journal of Thoracic Disease, 2018, 10, 3909-3921.	1.4	35
46	SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.. Journal of Clinical Oncology, 2014, 32, 7514-7514.	1.6	35
47	Stereotactic body radiation therapy-based treatment model for stage I medically inoperable small cell lung cancer. Practical Radiation Oncology, 2013, 3, 301-306.	2.1	33
48	Impact of the COVID-19 Pandemic on Healthcare Workersâ€™ Risk of Infection and Outcomes in a Large, Integrated Health System. Journal of General Internal Medicine, 2020, 35, 3293-3301.	2.6	33
49	Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model.. Journal of Clinical Oncology, 2018, 36, 9031-9031.	1.6	33
50	Colonization of Neural Allografts by Host Microglial Cells: Relationship to Graft Neovascularization. Cell Transplantation, 1997, 6, 221-230.	2.5	31
51	Risks and benefits of Twitter use by hematologists/oncologists in the era of digital medicine. Seminars in Hematology, 2017, 54, 198-204.	3.4	29
52	High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 646-653.	1.1	28
53	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell, 2020, 38, 761-766.	16.8	26
54	Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation. Oncologist, 2020, 25, 562-e1012.	3.7	26

#	Article	IF	Citations
55	Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab. , 2022, 10, e003778.		26
56	Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. Cancer Treatment and Research Communications, 2019, 19, 100126.	1.7	24
57	The CoVIDâ€TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVIDâ€19. Journal of Thrombosis and Haemostasis, 2021, 19, 2522-2532.	3.8	23
58	The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator. JCO Oncology Practice, 2022, 18, 578-583.	2.9	23
59	Phase I Study of the c-raf-1 Antisense Oligonucleotide ISIS 5132 in Combination with Carboplatin and Paclitaxel in Patients with Previously Untreated, Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 1156-1162.	1.1	22
60	Impact of EGFR mutation and ALK rearrangement on the outcomes of nonâ€“small cell lung cancer patients with brain metastasis. Neuro-Oncology, 2020, 22, 267-277.	1.2	22
61	Lectin staining of sheep microglia. Histochemistry, 1994, 102, 483-486.	1.9	21
62	Characterization of Myomodulin-Related Peptides From the Pulmonate Snail Helix aspersa. Peptides, 1997, 18, 1099-1106.	2.4	21
63	Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. Lung Cancer, 2018, 123, 14-21.	2.0	21
64	Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of â‰¥1% by the USA Food and Drug Administration. Annals of Oncology, 2019, 30, 1686-1688.	1.2	20
65	Identifying delays in care for patients with NSCLC using value-stream mapping.. Journal of Clinical Oncology, 2018, 36, 136-136.	1.6	20
66	Colonization of neural allografts by host microglial cells: Relationship to graft neovascularization. Cell Transplantation, 1997, 6, 221-230.	2.5	19
67	Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. Oncologist, 2015, 20, 1298-1303.	3.7	19
68	Interns' Work Hours. New England Journal of Medicine, 2005, 352, 726-728.	27.0	18
69	Distinguishing granulomas from adenocarcinomas by integrating stable and discriminating radiomic features on non-contrast computed tomography scans. European Journal of Cancer, 2021, 148, 146-158.	2.8	18
70	Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts).. Journal of Clinical Oncology, 2017, 35, 8504-8504.	1.6	18
71	mHealth: Mobile Technologies to Virtually Bring the Patient Into an Oncology Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 144-154.	3.8	17
72	Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium. The Lancet Healthy Longevity, 2022, 3, e143-e152.	4.6	16

#	Article	IF	Citations
73	Integration of EGFR Inhibitors and Conventional Chemotherapy in the Treatment of Nonâ€“Small-cell Lung Cancer. Clinical Lung Cancer, 2011, 12, 350-359.	2.6	15
74	Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers. Nature Communications, 2019, 10, 5143.	12.8	15
75	Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases. Scientific Reports, 2021, 11, 18174.	3.3	15
76	Nabâ€paclitaxel in older patients with nonâ€“small cell lung cancer who have developed disease progression after platinumâ€based doublet chemotherapy. Cancer, 2020, 126, 1060-1067.	4.1	13
77	Tracing of fluoro-gold prelabeled microglia injected into the adult rat brain. , 1998, 23, 84-88.		12
78	Biofeedback Assisted Stress Management in Patients with Lung Cancer: A Feasibility Study. Applied Psychophysiology Biofeedback, 2015, 40, 201-208.	1.7	12
79	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. Lung Cancer, 2017, 111, 108-115.	2.0	11
80	LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19). Annals of Oncology, 2020, 31, S1202-S1203.	1.2	11
81	Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab. Translational Lung Cancer Research, 2021, 10, 3071-3078.	2.8	11
82	Patterns of Recurrence and Overall Survival in Incidental Lung Cancer in Explanted Lungs. Annals of Thoracic Surgery, 2019, 107, 891-896.	1.3	10
83	A model comparing the value of broad next-gen sequencing (NGS)-based testing to single gene testing (SGT) in patients with nonsquamous non-small cell lung cancer (NSCLC) in the United States.. Journal of Clinical Oncology, 2020, 38, 9529-9529.	1.6	10
84	Selection of chemotherapy for patients with advanced nonâ€“small cell lung cancer. Cleveland Clinic Journal of Medicine, 2012, 79, S46-S50.	1.3	10
85	The promise and challenges of deep learning models for automated histopathologic classification and mutation prediction in lung cancer. Journal of Thoracic Disease, 2019, 11, 369-372.	1.4	9
86	Cases from the Immune-Related Adverse Event Tumor Board: Diagnosis and Management of Immune Checkpoint Blockade-Induced Diabetes. Oncologist, 2020, 25, 921-924.	3.7	9
87	Increase in time to initiating cancer therapy and association with worsened survival in curative settings: A U.S. analysis of common solid tumors.. Journal of Clinical Oncology, 2017, 35, 6557-6557.	1.6	9
88	mHealth: Mobile Technologies to Virtually Bring the Patient Into an Oncology Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 144-154.	3.8	9
89	Lung cancer treatment outcomes in recipients of lung transplant. Translational Lung Cancer Research, 2015, 4, 784-91.	2.8	9
90	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. JAMA Network Open, 2022, 5, e2142046.	5.9	9

#	Article	IF	Citations
91	Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases. Scientific Reports, 2021, 11, 7490.	3.3	8
92	EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data. Translational Lung Cancer Research, 2013, 2, 251-5.	2.8	8
93	The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature. Clinical Lung Cancer, 2022, 23, 108-115.	2.6	8
94	Reduction of Inappropriate Prophylactic Pegylated Granulocyte Colony-Stimulating Factor Use for Patients With Nonâ€“Small-Cell Lung Cancer Who Receive Chemotherapy: An ASCO Quality Training Program Project of the Cleveland Clinic Taussig Cancer Institute. Journal of Oncology Practice, 2016, 12, e101-e107.	2.5	7
95	Best Practices in Treatment Selection for Patients with Advanced NSCLC. Cancer Control, 2016, 23, 2-14.	1.8	7
96	Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash. Oncologist, 2019, 24, 4-8.	3.7	7
97	A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress).. Journal of Clinical Oncology, 2022, 40, TPS8595-TPS8595.	1.6	7
98	Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center Experience. JCO Precision Oncology, 2018, 2, 1-11.	3.0	6
99	Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors.. Journal of Clinical Oncology, 2016, 34, 11603-11603.	1.6	6
100	Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges. Annals of Translational Medicine, 2017, 5, 378-378.	1.7	6
101	Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers. Clinical Cancer Research, 2022, 28, 4410-4424.	7.0	6
102	Investigational agents in the management of non-small cell lung cancer. Current Oncology Reports, 2009, 11, 275-284.	4.0	5
103	PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Nonâ€“Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 569.	7.1	5
104	â€œMy Patient Was Diagnosed With Nontargetable Advanced Nonâ€“Small Cell Lung Cancer. What Now?â€• Diagnosis and Initial Treatment Options for Newly Diagnosed Patients With Advanced NSCLC. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 696-707.	3.8	5
105	Hereditary implications of somatic tumor testing.. Journal of Clinical Oncology, 2015, 33, 1523-1523.	1.6	5
106	Pre-treatment hematological markers as a predictive biomarker for survival in patients with non-small cell lung cancer treated with nivolumab.. Journal of Clinical Oncology, 2017, 35, 11547-11547.	1.6	5
107	The Morbidity and Mortality Conference (MMC) in Oncology: A patient safety and root cause analysis (RCA)-driven approach at the Cleveland Clinic Taussig Cancer Institute (TCI).. Journal of Clinical Oncology, 2014, 32, 191-191.	1.6	5
108	Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer. Journal of Thoracic Oncology, 2022, 17, 179-181.	1.1	5

#	Article	IF	Citations
109	Advanced Non-Small Cell Lung Cancer (NSCLC): Maintenance Therapy for All?. Current Treatment Options in Oncology, 2012, 13, 478-490.	3.0	4
110	High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer. Lung Cancer, 2018, 126, 48-54.	2.0	4
111	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. Oncologist, 2021, 26, 523-532.	3.7	4
112	Prospective clinical study of precision oncology in solid tumors.. Journal of Clinical Oncology, 2015, 33, 6585-6585.	1.6	4
113	Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 9079-9079.	1.6	4
114	Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer. Oncologist, 2022, 27, 407-413.	3.7	4
115	Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib. Journal of Thoracic Oncology, 2012, 7, 1200-1201.	1.1	3
116	Molecular Subtyping to Predict Risk of Venous Thromboembolism in Patients with Advanced Lung Adenocarcinoma: A Cohort Study. Blood, 2019, 134, 3651-3651.	1.4	3
117	Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry. Blood, 2020, 136, 56-58.	1.4	3
118	Evaluation of radiomic features on baseline CT scan to predict clinical benefit for pemetrexed based chemotherapy in metastatic lung adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, 11582-11582.	1.6	3
119	Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials.. Journal of Clinical Oncology, 2017, 35, e20647-e20647.	1.6	3
120	A study of rovalpituzumab tesirine in frontline treatment of patients with DLL3 expressing extensive small cell lung cancer.. Journal of Clinical Oncology, 2017, 35, TPS2598-TPS2598.	1.6	3
121	Assessing the roles ofEGFRgene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors. Biomarkers in Medicine, 2007, 1, 203-207.	1.4	2
122	Impact of a Stage IV NSCLC care pathway on front-line (FL) and maintenance (M) chemotherapy use at the Cleveland Clinic Taussig Cancer Institute (TCI).. Journal of Clinical Oncology, 2015, 33, 6609-6609.	1.6	2
123	Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: Results of a randomized phase 2 study.. Journal of Clinical Oncology, 2016, 34, 9059-9059.	1.6	2
124	Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer. Reviews on Recent Clinical Trials, 2017, 12, 51-58.	0.8	2
125	Treating acquired resistance to EGFR-tyrosine kinase inhibitors:still a work in progress. Translational Lung Cancer Research, 2012, 1, 149-51.	2.8	2
126	Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub. Blood, 2020, 136, 7-8.	1.4	2

#	Article	IF	Citations
127	Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 3353-3356.	1.6	2
128	Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010): Focus on Developmental Therapeutics Related to Lung Cancer. Clinical Lung Cancer, 2011, 12, 94-99.	2.6	1
129	Treating Anaplastic Lymphoma Kinaseâ€“Positive Lung Cancer in the Weeks After the US Food and Drug Administration Approval of Crizotinib. Journal of Oncology Practice, 2012, 8, 34s-37s.	2.5	1
130	Fast-Growing Plasmacytoma. American Journal of the Medical Sciences, 2016, 351, 308.	1.1	1
131	Exploring Ways to Improve Access to and Minimize Risk from Lung Cancer Screening. Oncologist, 2020, 25, 364-365.	3.7	1
132	Effect of improving guideline-based prophylactic growth factor (pGCSF) use with chemotherapy (CT) on the risk of febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients (pts): A Cleveland Clinic Taussig Cancer Institute (TCI) Quality Improvement (QI) Project.. Journal of Clinical Oncology, 2015, 33, 6565-6565.	1.6	1
133	Phase II study of stereotactic radiosurgery or other local ablation followed by erlotinib for patients with EGFR mutation who have previously progressed on an EGFR tyrosine kinase inhibitor (TKI).. Journal of Clinical Oncology, 2017, 35, e20623-e20623.	1.6	1
134	Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?. Journal of Thoracic Disease, 2020, 12, 5042-5045.	1.4	1
135	Patients as real time teachers. Journal of Cancer Education, 2007, 22, 131-133.	1.3	0
136	Phase I/II Trial of the Addition of Erlotinib to Pre- and Postoperative Chemotherapy/Hyperfractionated Radiotherapy, and as Maintenance, for Resectable Mediastinoscopy-defined Stage III Nonâ€“small-cell Lung Cancer (NSCLC): Report on the Phase II Component. International Journal of Radiation Oncology Biology Physics, 2009, 75, S58.	0.8	0
137	Superior vena cava syndrome in lung cancer. Lung Cancer Management, 2012, 1, 309-315.	1.5	0
138	New Guideline Sets the Ground Rules for Routine Molecular Testing in Non-Small Cell Lung Cancer. Journal of Molecular Diagnostics, 2013, 15, 413-414.	2.8	0
139	Adjuvant Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer. Chest, 2016, 149, 1357-1359.	0.8	0
140	P2.03a-040 Safety and Efficacy of Nab-Paclitaxel for 2nd Line Treatment of Elderly Patients with Stage IV Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S912-S913.	1.1	0
141	An Openâ€Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Nonâ€Small Cell Lung Cancer. Oncologist, 2019, 24, 457.	3.7	0
142	Adjuvant Targeted Therapy for Patients With Epidermal Growth Factor Receptorâ€“Mutant Lung Cancer. JAMA Oncology, 2021, 7, 679.	7.1	0
143	Circulating tumor cells enrichment and characterization in ALK-translocation positive lung cancer.. Journal of Clinical Oncology, 2014, 32, e19025-e19025.	1.6	0
144	Treatment (trmt) outcome in lung transplant (LTx) recipients who develop lung cancer (LC): A Cleveland Clinic (CC) experience.. Journal of Clinical Oncology, 2014, 32, e12515-e12515.	1.6	0

#	Article	IF	Citations
145	Patient-centered outcomes with post-approval nivolumab in metastatic NSCLC at the Cleveland Clinic Taussig Cancer Institute (TCI).. Journal of Clinical Oncology, 2016, 34, 29-29.	1.6	0
146	Pre-clinical proof of principle of pharmacologically rational non-cytotoxic epigenetic-immunotherapy to treat lung cancer.. Journal of Clinical Oncology, 2016, 34, e14073-e14073.	1.6	0
147	Preoperative neutrophil lymphocyte ratio as a predictor of outcomes in patients with early stage non-small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, e23069-e23069.	1.6	0
148	The effect of routine early palliative care (PC) consultation on aggressiveness of care at the end of life (EOL) in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, e21688-e21688.	1.6	0
149	Precision oncology experience at a tertiary care center.. Journal of Clinical Oncology, 2017, 35, e18118-e18118.	1.6	0
150	Association of delays in time to surgery for resectable stage IIIA non-small cell lung cancer with survival.. Journal of Clinical Oncology, 2017, 35, e20056-e20056.	1.6	0
151	PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage nonâ€“small-cell lung cancer (ES-NSCLC).. Journal of Clinical Oncology, 2018, 36, 12059-12059.	1.6	0
152	Longitudinal precision oncology experience in solid tumors at the Cleveland Clinic.. Journal of Clinical Oncology, 2018, 36, e18710-e18710.	1.6	0
153	ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients. Translational Lung Cancer Research, 2013, 2, E1-3.	2.8	0
154	Risk of Venous Thromboembolism in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors. Blood, 2021, 138, 3223-3223.	1.4	0
155	Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic. Blood, 2020, 136, 41-42.	1.4	0
156	Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zhenget al. , 2022, 10, e005086.		0